+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report by Type, Drug, Dosage, Distribution Channel, Sales Channel, Product, Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 123 Pages
  • September 2022
  • Region: North America
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5673524
Description Jump to:
The North America Dry Eye Syndrome Treatment Market would witness market growth of 3.2% CAGR during the forecast period (2022-2028).

A robust and prospective pipeline has been created as a result of increased R&D efforts for the condition's treatment. This includes items like CyclASol, SURF-100, SURF-200, Pro-ocular, and OCS-02, which are projected to increase the patient population's inventory of available therapy alternatives. Additionally, NOV03 met every clinical target, and its introduction is expected to be soon. Geriatric population growth is anticipated to be a major market driver since older people's eyes produce fewer tears, which causes more evaporation and dryness.

A significant factor driving the growth of the dry eye syndrome treatment market is the rising occurrence of dry eye syndrome and the rising need for dry eye treatment to relieve various symptoms. During the forecast period, there will be opportunities for growth in the markets for eye care products and treatments for dry eye syndrome. This is due to the rapid increase in cases of the condition and the rising adoption of various treatments, such as artificial tears and dry eye treatment drops, for treating multiple symptoms. Additionally, the growing acceptance of femtosecond and excimer ophthalmic lasers for the treatment of dry eye conditions bodes well for the market's future.

In Canada, a prospective, multicenter, observational cross-sectional study was carried out at six locations across the country. This study offered crucial insights into the detrimental effects of DED in the context of Canada. In comparison to people with a moderate or mild condition, those with severe DED had higher indirect and direct costs as well as lower quality of life. Patients with DED and Sjögren's syndrome had worse quality of life (QoL) and higher expenses than those with DED alone. These studies present the possibility of rising cases of DED and its detrimental effects. These will propel the demands for treatment throughout the region, therefore, expediting the expansion of the dry eye syndrome treatment market.

The US market dominated the North America Dry Eye Syndrome Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,558.4 million by 2028. The Canada market is experiencing a CAGR of 5.6% during (2022-2028). Additionally, The Mexico market would exhibit a CAGR of 4.6% during (2022-2028).

Based on Type, the market is segmented into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on Drug, the market is segmented into Restasis, Xiidra, Cequa, Eysuvis and Tyrvaya & Others. Based on Dosage, the market is segmented into Eye drops, Gels, Capsules & Tablets, Eye Solutions and Ointments. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Sales Channel, the market is segmented into OTC and Prescription. Based on Product, the market is segmented into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Oral Omega Supplements and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson (Johnson & Johnson Services, Inc.), AbbVie, Inc., Bausch + Lomb Corporation (Bausch Health Companies, Inc.), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Inc., and Otsuka Pharmaceutical Co., Ltd.

Scope of the Study

Market Segments Covered in the Report:

By Type

  • Evaporative Dry Eye Syndrome
  • Aqueous Deficient Dry Eye Syndrome

By Drug

  • Restasis
  • Xiidra
  • Cequa
  • Eysuvis
  • Tyrvaya & Others

By Dosage

  • Eye drops
  • Gels
  • Capsules & Tablets
  • Eye Solutions
  • Ointments

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

By Sales Channel

  • OTC
  • Prescription

By Product

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Oral Omega Supplements
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • AbbVie, Inc.
  • Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
  • Novartis AG
  • Sun Pharmaceuticals Industries Ltd.
  • AFT Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • OASIS Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Dry Eye Syndrome Treatment Market, by Type
1.4.2 North America Dry Eye Syndrome Treatment Market, by Drug
1.4.3 North America Dry Eye Syndrome Treatment Market, by Dosage
1.4.4 North America Dry Eye Syndrome Treatment Market, by Distribution Channel
1.4.5 North America Dry Eye Syndrome Treatment Market, by Sales Channel
1.4.6 North America Dry Eye Syndrome Treatment Market, by Product
1.4.7 North America Dry Eye Syndrome Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. North America Dry Eye Syndrome Treatment Market by Type
4.1 North America Evaporative Dry Eye Syndrome Market by Country
4.2 North America Aqueous Deficient Dry Eye Syndrome Market by Country
Chapter 5. North America Dry Eye Syndrome Treatment Market by Drug
5.1 North America Restasis Market by Country
5.2 North America Xiidra Market by Country
5.3 North America Cequa Market by Country
5.4 North America Eysuvis Market by Country
5.5 North America Tyrvaya & Others Market by Country
Chapter 6. North America Dry Eye Syndrome Treatment Market by Dosage
6.1 North America Eye drops Market by Country
6.2 North America Gels Market by Country
6.3 North America Capsules & Tablets Market by Country
6.4 North America Eye Solutions Market by Country
6.5 North America Ointments Market by Country
Chapter 7. North America Dry Eye Syndrome Treatment Market by Distribution Channel
7.1 North America Retail Pharmacy Market by Country
7.2 North America Hospital Pharmacy Market by Country
7.3 North America Online Pharmacy Market by Country
Chapter 8. North America Dry Eye Syndrome Treatment Market by Sales Channel
8.1 North America OTC Market by Country
8.2 North America Prescription Market by Country
Chapter 9. North America Dry Eye Syndrome Treatment Market by Product
9.1 North America Cyclosporine Market by Country
9.2 North America Topical Corticosteroids Market by Country
9.3 North America Artificial Tears Market by Country
9.4 North America Punctal Plugs Market by Country
9.5 North America Oral Omega Supplements Market by Country
9.6 North America Others Market by Country
Chapter 10. North America Dry Eye Syndrome Treatment Market by Country
10.1 US Dry Eye Syndrome Treatment Market
10.1.1 US Dry Eye Syndrome Treatment Market by Type
10.1.2 US Dry Eye Syndrome Treatment Market by Drug
10.1.3 US Dry Eye Syndrome Treatment Market by Dosage
10.1.4 US Dry Eye Syndrome Treatment Market by Distribution Channel
10.1.5 US Dry Eye Syndrome Treatment Market by Sales Channel
10.1.6 US Dry Eye Syndrome Treatment Market by Product
10.2 Canada Dry Eye Syndrome Treatment Market
10.2.1 Canada Dry Eye Syndrome Treatment Market by Type
10.2.2 Canada Dry Eye Syndrome Treatment Market by Drug
10.2.3 Canada Dry Eye Syndrome Treatment Market by Dosage
10.2.4 Canada Dry Eye Syndrome Treatment Market by Distribution Channel
10.2.5 Canada Dry Eye Syndrome Treatment Market by Sales Channel
10.2.6 Canada Dry Eye Syndrome Treatment Market by Product
10.3 Mexico Dry Eye Syndrome Treatment Market
10.3.1 Mexico Dry Eye Syndrome Treatment Market by Type
10.3.2 Mexico Dry Eye Syndrome Treatment Market by Drug
10.3.3 Mexico Dry Eye Syndrome Treatment Market by Dosage
10.3.4 Mexico Dry Eye Syndrome Treatment Market by Distribution Channel
10.3.5 Mexico Dry Eye Syndrome Treatment Market by Sales Channel
10.3.6 Mexico Dry Eye Syndrome Treatment Market by Product
10.4 Rest of North America Dry Eye Syndrome Treatment Market
10.4.1 Rest of North America Dry Eye Syndrome Treatment Market by Type
10.4.2 Rest of North America Dry Eye Syndrome Treatment Market by Drug
10.4.3 Rest of North America Dry Eye Syndrome Treatment Market by Dosage
10.4.4 Rest of North America Dry Eye Syndrome Treatment Market by Distribution Channel
10.4.5 Rest of North America Dry Eye Syndrome Treatment Market by Sales Channel
10.4.6 Rest of North America Dry Eye Syndrome Treatment Market by Product
Chapter 11. Company Profiles
11.1 Johnson & Johnson (Johnson & Johnson Services, Inc.)
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental &Regional Analysis
11.1.4 Research & Development Expenses
11.1.5 Recent strategies and developments:
11.1.5.1 Product Launches and Product Expansions:
11.1.5.2 Approvals and Trials:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Product Launches and Product Expansions:
11.3 Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental and Regional Analysis
11.3.4 Research & Development Expense
11.3.5 Recent strategies and developments:
11.3.5.1 Partnerships, Collaborations, and Agreements:
11.3.5.2 Product Launches and Product Expansions:
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Acquisition and Mergers:
11.5 Sun Pharmaceuticals Industries Ltd
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
11.5.5.1 Product Launches and Product Expansions:
11.5.5.2 Approvals and Trials:
11.6 AFT Pharmaceuticals
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Segmental Analysis
11.6.4 Research & Development Expenses
11.6.5 Recent strategies and developments:
11.6.5.1 Product Launches and Product Expansions:
11.7 Santen Pharmaceutical Co., Ltd.
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Regional Analysis
11.7.4 Research & Development Expenses
11.7.5 Recent strategies and developments:
11.7.5.1 Acquisition and Mergers:
11.7.5.2 Approvals and Trials:
11.8 Oyster Point Pharma, Inc.
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Research & Development Expenses
11.8.4 Recent strategies and developments:
11.8.4.1 Partnerships, Collaborations, and Agreements:
11.8.4.2 Approvals and Trials:
11.9 OASIS Medical, Inc.
11.9.1 Company Overview
11.9.2 Recent strategies and developments:
11.9.2.1 Product Launches and Product Expansions:
11.10. Otsuka Pharmaceutical Co., Ltd.
11.10.1 Company Overview

Companies Mentioned

  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • AbbVie, Inc.
  • Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
  • Novartis AG
  • Sun Pharmaceuticals Industries Ltd.
  • AFT Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • OASIS Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Dry Eye Syndrome Treatment Market Size, Share and Trends Analysis Report by Type (Evaporative, Aqueous Deficient), Drug, Product, Dosage Form, Sales Channel, Distribution Channel, and Region 2024-2030 - Product Image

Dry Eye Syndrome Treatment Market Size, Share and Trends Analysis Report by Type (Evaporative, Aqueous Deficient), Drug, Product, Dosage Form, Sales Channel, Distribution Channel, and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 314 Pages
  • Global
North America Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Country 2024-2032 - Product Image

North America Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Country 2024-2032

  • Report
  • 122 Pages
  • North America
From
Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Region 2024-2032 - Product Image

Dry Eye Syndrome Market Report by Disease Type, Drug Type, Product, Distribution Channel, and Region 2024-2032

  • Report
  • 144 Pages
  • Global
From
Dry Eye Syndrome Market by Drug, Product - Global Forecast 2025-2030 - Product Image

Dry Eye Syndrome Market by Drug, Product - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.